Kinnate Biopharma amends bylaws on advance notice, universal proxy, and DGCL updates

Kinnate Biopharma Inc.

Board approved amended and restated bylaws effective July 25, 2023.
Updates include changes to advance notice procedures for director nominations and stockholder proposals.
Provisions revised to address SEC universal proxy rules and recent DGCL amendments.
Exclusive forum provisions clarified; other ministerial and conforming changes made.
No operational or financial impact; full text of bylaws filed as Exhibit 3.1.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Kinnate Biopharma Inc.: Amended and restated bylaws to update advance notice procedures, stockholder meeting provisions, director and officer provisions, exclusive forum, and other ministerial changes (effective 2023-07-25).

Change: bylaw amendment
Effective: 2023-07-25

Exact text from the filing

On July 25, 2023, the board of directors (the “Board”) of Kinnate Biopharma Inc. (the “Company”) approved and adopted amended and restated bylaws (the “Amended and Restated Bylaws”), effective immediately, to reflect, among other things:

View on SEC.gov

Browse all governance changes →

Source: SEC EDGAR

accession 0001140361-23-036770

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.